Blogs about: Merck Kgaa
Featured Blog
Erbitux plus Irinotecan effective in Colorectal cancer
Newly publsihed data from the MABEL study shows Erbitux plus Irinotecan is effective in Colorectal cancer… more →
Kinase News
Alliance between Merck KGaA and Dyesol Limited
silico wrote 1 month ago: Global pharmaceutical and chemical company Merck KGaA and Dyesol Limited signed an agreement on Octo … more →
Monday Deal Review: March 30, 2009
— 3 comments
Jeremy G wrote 8 months ago: Canadian deal and company info from this week Patheon-JLL Battle Continues: Patheon fought back agai … more →
New Merck Serono Biotechnology Ventures Fund
Jeremy G wrote 8 months ago: Merck KGaA, the Darmstadt-based company (not part of Merck & Co. Inc. of the U.S.), is starting … more →
multiple sclerosis - weapons of MS destruction?
— 1 comment
Jeffrey Seguritan wrote 10 months ago: Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (brain, spinal … more →
Today's Top Three in Pharma 012609
Steve Woodruff wrote 10 months ago: Of course, the huge news this Monday morning…Pfizer buying Wyeth. This will dominate the headl … more →
Erbitux plus Irinotecan effective in Colorectal cancer
crimsoncanary wrote 1 year ago: Newly publsihed data from the MABEL study shows Erbitux plus Irinotecan is effective in Colorectal c … more →
Lilly to acquire ImClone
crimsoncanary wrote 1 year ago: Eli Lilly has announced that it will acquire ImClone Systems through an all cash tender offer of $70 … more →
5 year data in Head and Neck cancer shows erbitux increases overall survival
crimsoncanary wrote 1 year ago: Five year data presented at the American Society for Therapeutic Radiology and Oncology (ASTRO) Meet … more →
Erbitux now available in Japan for Advanced Colorectal Cancer
crimsoncanary wrote 1 year ago: ImClone Systems have announced that erbitux (cetuximab) has been commercially launched in Japan for … more →
Erbitux continues to be effective in metastatic colorectal cancer
crimsoncanary wrote 1 year ago: Data presented at the European of Medical Oncology (ESMO) show that Erbitux, plus FOLFIRI, continued … more →
Merck Serono submit Erbitux for NSCLC in Europe
crimsoncanary wrote 1 year ago: Merck Serono has submitted an EMEA application for Erbitux (cetuximab) for use in the firstline trea … more →
Erbitux improves first line Head and Neck Cancer Survival (NEJM)
crimsoncanary wrote 1 year ago: Imclone and BMS have announced the publication of Phase III results of Erbitux (cetuximab) plus pla … more →
ImClone submit sBLA for Erbitux in First-Line Head and Neck Cancer
crimsoncanary wrote 1 year ago: ImClone Systems has submitted an sBLA to the US FDA to broaden the use of ERBITUX (cetuximab) to inc … more →
Erbitux plus Taxane/Carboplatin effective in NSCLC
crimsoncanary wrote 1 year ago: ImClone have announced that Phase III results show erbitux (cetuximab) in combination with a taxane … more →
Merck Serono receive EU approval for Erbitux in Metastatic Colorectal Cancer
crimsoncanary wrote 1 year ago: Merck Serono have received EU approval for Erbitux in EGFR expressing, KRAS wild-type metastatic col … more →
Erbitux approved in Japan for Advanced Colorectal Cancer
crimsoncanary wrote 1 year ago: ImClone Systems have announced that Erbitux (cetuximab) has been approved in Japan for use in treati … more →
Merck-Serono initiate Phase III trial of Erbitux in Gastric Cancer
crimsoncanary wrote 1 year ago: Merck KGaA (Merck-Serono) has initiated a Phase III study of Erbitux in combination with Xeloda and … more →
Takeda flexes its partnering muscles
silico wrote 2 years ago: Are the Japanese healthcare majors emerging as serious competitors to the largest North American and … more →
Merck KGaA acquires Serono for US$13.5 billion
silico wrote 2 years ago: In September 2006 the German pharmaceutical company, Merck KGaA, acquired Europe’s largest bio … more →
